Drug Profile
Research programme: prostaglandin E synthase inhibitors - Cadila Pharmaceuticals/NovaSAID
Alternative Names: Anti-inflammatory therapeutics / analgesics - Cadila Pharmaceuticals/NovaSAIDLatest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator NovaSAID
- Developer Cadila Pharmaceuticals; NovaSAID
- Class Nonsteroidal anti-inflammatories
- Mechanism of Action Prostaglandin-E synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fever; Inflammation; Pain
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Inflammation in India (PO)
- 28 Feb 2018 No recent reports of development identified for preclinical development in Inflammation in Sweden (PO)
- 28 Feb 2018 No recent reports of development identified for preclinical development in Pain in India (PO)